The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
Wednesday’s top analyst upgrades, downgrades and initiations include Celgene, Ciena, Goldman Sachs, MannKind, Newfield Exploration, Tetraphase Pharmaceuticals, Walgreens Boots Alliance and Yingli Green Energy.
The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
All corporations stop insider transactions around the reporting date to avoid the look of any impropriety, and they appear to be resuming with a vengeance.
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
Celgene released better-than-expected second-quarter earnings report Thursday before the markets opened.
Chris Lange Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Celgene and Receptos announced Tuesday that they had signed a definitive agreement in which the former will acquire the latter in a deal worth roughly $7.2 billion.
Chris Lange 24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Celgene and Juno Therapeutics are coming together in a global collaboration for the development and commercialization of immunotherapies.
Chris Lange The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Celgene announced that its board authorized the repurchase of up to an additional $4.0 billion of its common stock.
Chris Lange The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
